| Document |
Document Title |
|
WO/2001/057020A1 |
Novel compounds of formula (I) including its pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalian factor Xa is described. Compositions containing such compounds are also...
|
|
WO/2001/055095A1 |
The present invention refers to new classes of polymerisable monomers, to molecularly imprinted polymers obtainable by polymerisation of at least one of the monomers and a crosslinking monomer in the presence of a template molecule. The ...
|
|
WO1999063937A9 |
Disclosed are multibinding compounds which include macrolide antibiotics, aminoglycosides, lincosamides, oxazolidinones, streptogramins, tetracycline and/or other compounds which bind to bacterial ribosomal RNA and/or to one or more prot...
|
|
WO/2001/034614A2 |
The invention includes compositions and methods useful for treatment of a virus infection in a mammal by double-targeting the virus (i.e. targeting the virus at more than one stage of the virus life cycle) and thereby inhibiting virus re...
|
|
WO/2001/028599A1 |
Methods are provided for neutralization of microorganisms in fluids or on surfaces. Preferably the fluids contain blood or blood products and comprise biologically active proteins. Preferred methods include the steps of adding an activat...
|
|
WO1999063939A9 |
Disclosed are multibinding compounds which inhibit cyclooxygenase-2 (COX-2), an enzyme which catalyzes the first committed step in the biosynthesis of prostaglandins. The multibinding compounds of this invention containing from 2 to 10 l...
|
|
WO/2001/023389A2 |
The present invention also provides a general method to whereby mono-, bi-, or tri-cyclic heterocycles may be modified to obtain potent antagonists at the NPY¿1? receptor. The present invention provides novel, potent, non-peptidic antag...
|
|
WO/2001/021619A1 |
Compounds of formula (I), where preferably: A = a bridge of partial formula (II) or (III), R?1¿ and R?2¿ = independently (substituted) alkyl, aryl or aralkyl, or together form a heterocycle, R?3¿ = H, -CO-Alkyl, or -CO-Aryl, R?4¿ = A...
|
|
WO/2001/019825A1 |
Disclosed are compounds of Formulae (Ia), (Ib), (Ic), (Id) wherein: W is NH, S, SO, or SO¿2?; R?2¿ is (un)substituted aryl, (un)substituted heteroaryl, or (un)substituted carbocycle or heterocycle; Q is hydrogen or lower alkyl; R?4¿ a...
|
|
WO/2001/017568A2 |
In order to meet these needs, the present invention is directed to therapeutic and diagnostic agents capable of forming covalent bonds to blood and pulmonary fluid proteins or other components ex vivo or in vivo. The therapeutic agents o...
|
|
WO/2001/017614A2 |
Derivatives of antineoplastic agents are prepared. The derivatives are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
|
|
WO/2001/012198A1 |
Therapeutic or preventive agents for myocardial infarction containing as the active ingredient compounds of general formula (I) or salts thereof wherein R¿1? is CH¿2?, CH¿2?CH¿2?,CH¿2?O, CH¿2?S or CH¿2?SO; R¿2? is hydrogen, C¿1?...
|
|
WO/2001/008684A1 |
The present invention features methods for induction of angiogenesis by administration of nicotine or other nicotine receptor agonist. Induction of angiogenesis by the methods of the invention can be used in therapeutic angiogenesis in, ...
|
|
WO1999064049A9 |
This invention relates to novel multibinding compounds (agents) that are antibacterial agents. The multibinding compounds of the invention comprise from 2-10 ligands covalently connected by a linker or linkers, wherein each of said ligan...
|
|
WO/2001/004120A1 |
The invention concerns a method for making tetrahydropterin and tetrahydropterin derivatives by hydration of pterin and pterin derivatives with hydrogen in the presence of a hydration catalyst. Said method consists in performing the hydr...
|
|
WO/2001/004121A1 |
The invention concerns a method for making and enriching ester salts of (6S, $g(a)S)- or (6S, $g(a)R)-tetrahydrofolic acid and (6S, $g(a)S)- or (6S, $g(a)R)-tetrahydrofolic acid. The invention is characterised in that it consists in: pro...
|
|
WO/2000/071160A1 |
Novel medicinal compositions containing anti-Fas antibody which are useful as preventives or remedies for autoimmune diseases or rheumatoid arthritis. More particularly, medicinal compositions containing as the active ingredients antihum...
|
|
WO/2000/064484A2 |
Conjugates of a hydrophobic moiety, such as a lipid, linked through a cleavable dithiobenzyl linkage to a therapeutic agent are described. The dithiobenzyl linkage is susceptible to cleavage by mild thiolysis, resulting in release of the...
|
|
WO2000040172B1 |
Composition and formulations comprising a first agent such as folinic acid, pharmaceutically acceptable salts thereof or mixtures thereof, and a second agent(s) such as analgesics, muscle relaxants, mood disorder agents, anti-inflammator...
|
|
WO/2000/059884A1 |
The invention relates to pharmaceutically active compounds, and methods of treatment and pharmaceutical compositions that utilize or comprise one or more such compounds. Compounds of the invention are particularly useful for the treatmen...
|
|
WO/2000/058289A1 |
The invention provides methods and compositions for measuring ion concentration inside a cell by measuring fluorescence of a compound of the general formula (I). In particular embodiments, the measured ion is halide, particularly iodide,...
|
|
WO/2000/056738A1 |
This invention concerns a bicyclic compound of Formula (I), wherein: G is N, CH or C(CN); ring X is a 5- or 6-membered fused heteroaryl ring which contains 1, 2, or 3 heteroatoms selected from oxygen, sulphur and nitrogen; m is 0 - 2; R?...
|
|
WO/2000/045800A2 |
The invention relates to a pharmaceutical composition for the treatment of autoimmuno disorders and/or for the treatment or prevention of transplant-rejections comprising a pteridine derivative of general formula (I) especially a lumazin...
|
|
WO1999064033A9 |
This invention relates to novel multibinding compounds that bind to the enzyme phosphodiesterase V (PDE V) and modulate its activity. The compounds of this invention comprise 2-10 PDE V modulator (particularly inhibitor) ligands covalent...
|
|
WO1999063994A9 |
Disclosed are multibinding compounds which inhibit 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG-CoA reductase), the rate limiting enzyme in cholesterol biosynthesis. The multibinding compounds of this invention containing from 2 ...
|
|
WO/2000/043013A1 |
The invention relates to products for complete nutrition of infants or diseased or elderly persons. The products are characterised by increased levels of folic acid, vitamin B6 and vitamin B12 or their functional equivalents. These produ...
|
|
WO/2000/042868A1 |
The invention relates to products for complete nutrition of infants. The products are characterised by the type and amount of protein and carbohydrate and the increased levels of folic acid, vitamin B6 and vitamin B12 or their functional...
|
|
WO1999064048A9 |
Disclosed are multibinding compounds which inhibit the enzyme HIV reverse transcriptase, an enzyme which catalyzes the conversion of viral RNA to single stranded DNA. The multibinding compounds of this invention containing from 2 to 10 l...
|
|
WO/2000/039129A1 |
The invention relates to a pharmaceutical composition for the treatment of autoimmune disorders or for the treatment and/or prevention of transplant-rejections and/or for the treatment of inflammatory diseases comprising as an active pri...
|
|
WO/2000/034281A1 |
Methotrexate conjugates of formula (I) are disclosed as well as their use in the treatment of a disease with an autoimmune component and cancers. A particular example of a compound of formula (I) is methotrexate-$g(g)-glycine Tris, in wh...
|
|
WO1999066063A9 |
The invention is directed to mononucleosides and oligonucleotides that are conjugated to folic acid, related folates, antifolates and analogs thereof, and to non-nucleosidic folate conjugates. Methods for the preparation of nucleosidic a...
|
|
WO/2000/025764A2 |
Compositions comprising one or more active ingredients and, optionally, one or more nutritional substances, solid, liquid and/or semiliquid excipients or auxiliaires, wherein the active ingredients consist of a) a component A consisting ...
|
|
WO1999063988A9 |
Disclosed are multibinding compounds which inhibit nitric oxide synthases (NOSs), enzymes which form nitric oxide and L-citrulline from L-arginine. The multibinding compounds of this invention contain from 2 to 10 ligands covalently atta...
|
|
WO/2000/023448A1 |
Disclosed are novel metal pterin and pterin analog complexes and compositions useful as antineoplastic and antiviral agents.
|
|
WO1999064047A9 |
Novel compounds are disclosed, useful as antiviral agents.
|
|
WO1999063929A9 |
Disclosed are multibinding compounds which inhibit microsomal triglyceride transferase protein (MTP), a protein which mediates the transfer of lipids during the assembly of lipoproteins and related biomolecules. The multibinding compound...
|
|
WO1999064054A9 |
Disclosed are multibinding compounds which inhibit topoisomerases which are essential enzymes in higher encaryotes for DNA replication and repair. The multibinding compounds of this invention containing from 2 to 10 ligands covalently at...
|
|
WO/2000/010983A1 |
The present invention relates to a process of producing specific isomers of substituted pyrazine compounds, substituted thieno[b]pyrazine, substituted pteridins, compounds, and derivatives thereof. The regiospecific substituted pyrazine ...
|
|
WO/2000/006585A1 |
Nitric acid salts with medicines active in bony disorders.
|
|
WO/2000/000491A1 |
Bifunctional activation cascade antagonist compounds inhibit inflammatory responses associated with TNF-$g(a) and fibroblast proliferation $i(in vivo) and $i(in vitro) by blocking activation of both the c-Jun and p38 kinases. The compoun...
|
|
WO/1999/064051A1 |
Novel multibinding compounds are disclosed. The compounds of the invention comprise from 2-10 ligands covalently connected, each of said ligands being capable of inhibiting bacterial Type II DNA topoisomerase, thereby modulating the biol...
|
|
WO/1999/063940A2 |
Disclosed are multibinding compounds which inhibit H?+¿/K?+¿-ATPase, an enzyme which is involved in the control of acid secretion in the stomach. The multibinding compounds of this invention containing from 2 to 10 ligands covalently a...
|
|
WO/1999/064037A1 |
Novel multi-binding compounds are disclosed that modulate enzymatic processes. The compounds of the invention comprise from 2-10 ligands covalently connected, each of said ligands being capable of binding to an enzyme, enzyme substrate o...
|
|
WO/1999/064032A1 |
Disclosed are methods for synthesizing large collections of diverse multimeric compounds as well as iterative processes for evaluating key molecular constraints imparting multibinding properties to multimeric compounds. Also disclosed ar...
|
|
WO/1999/052861A1 |
The invention relates to novel benzyl guanidine derivatives for therapy and $i(in-vivo) and $i(in-vitro) diagnosis. The invention also relates to the use of these compounds as therapeutic agents and diagnostic agents, especially for trea...
|
|
WO/1999/051572A1 |
Compounds having a matrix metaloproteinase-13 inhibitory activity and an aggrecanase inhibitory activity. They are compounds represented by general formula (I) or pharmacologically acceptable salts, esters, or other derivatives thereof w...
|
|
WO/1999/043324A1 |
Preventives or remedies for efficaciously preventing or ameliorating drug-induced renal disturbance which contain as the active ingredient compounds represented by general formula (I) or pharmaceutically acceptable salts thereof, wherein...
|
|
WO/1999/043325A1 |
Remedies for efficaciously preventing or ameliorating diseases in association with vascular function anomaly relating to insulin resistance. These remedies contain as the active ingredient compounds represented by general formula (I) or ...
|
|
WO/1999/040089A1 |
The invention provides a compound of formula (I) wherein X, R¿1?, R¿2? and Het are as defined in the description, and a process for preparing them. The compounds of formula (I) are useful as pharmaceuticals.
|
|
WO/1999/026940A2 |
The invention relates to a novel method for producing 8-methoxy-quinoline carboxylic acids which depict antibiotics having a high antibacterial action.
|
